General Information of Drug (ID: DML97KB)

Drug Name
TAS-106 Drug Info
Indication
Disease Entry ICD 11 Status REF
Head and neck cancer 2D42 Phase 2 [1]
Cross-matching ID
PubChem CID
176885
CAS Number
CAS 180300-43-0
TTD Drug ID
DML97KB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rifamycin DMEH3O7 Diarrhea ME05.1 Approved [3]
Favipiravir DMBZ27L Influenza virus infection 1E30-1E32 Registered [4]
JTK-003 DMB0V5Y Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [5]
R-1479 DM9C6LN Hepatitis C virus infection 1E51.1 Discontinued in Phase 1 [6]
XTL-2125 DM3Y6M7 Hepatitis C virus infection 1E51.1 Discontinued in Phase 1 [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mycobacterium RNA polymerase (MycB RNAP) TT79JGK RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU Modulator [2]

References

1 ClinicalTrials.gov (NCT00737360) Phase II Study of TAS-106 to Treat Head and Neck Cancer. U.S. National Institutes of Health.
2 Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26.
3 Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840.
4 Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
5 Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010 April; 2(4): 826-866.
6 The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cel... J Biol Chem. 2006 Feb 17;281(7):3793-9.
7 DOI: 10.1111/j.1365-2036.2009.03927.x